INBRX106-01-201

• Research type

  Research Study

• Full title

  A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)

• IRAS ID

  1010565

• Contact name

  Susan Weinbach

• Contact email

  susan@inhibrx.com

• Sponsor organisation

  Inhibrx Biosciences, Inc.

• Eudract number

  2024-515538-34

• Clinicaltrials.gov Identifier

  NCT06295731

• Research summary

  Study of Experimental Immunotherapy added to Standard Treatment for Advanced Head and Neck Cancer.

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  24/SC/0308

• Date of REC Opinion

  7 Jan 2025

• REC opinion

  Further Information Favourable Opinion